

Report from the SHARP Stakeholder Board Meeting- June 2023

Take home messages from the SHARP Stakeholders Meeting 2023

- SHARP is a unique Pan European research platform – connecting severe asthma specialists and patients across Europe, working together for a better future for patients living with severe asthma.
- With the establishment of the SHARP Federated Analysis Platform model, SHARP is delivering strong real-life evidence on severe asthma in Europe - to guide the further evolution of SHARP as a Pan European research community.

At this year's Stakeholder meeting, the discussion focussed on

- *The place of AI in the management of severe asthma*
 - Support the development of AI as a way of communication between patients and doctors.
 - Use AI as a tool for diagnosis and treatment to provide same opportunities for all patients.
 - AI as a support/help in countries with electronic prescriptions: eg. Systemic steroid
- *Personalized treatment in SA management*
 - Describe access to biologics: rural areas/ availability of biologics in different countries.
 - What criteria to start treatment across different countries?
 - Real world data collection: which data and right timing (every 3, 6 or 12 months)?
 - Prospective study on lung function decline in patients receiving different biologics as compared to biological-naïve.
 - Quality of life as major outcome
- *Information resources and outcomes in Severe Asthma*
 - Do patients know what to expect and demand from their health care provider?
 - Where do patients find reliable sources of information on severe asthma?
 - How do we get closer to understanding what matters for patients? Can we use social media to learn more about the key topics patients think about?

The core activities in SHARP over the next year are to deliver

- A SHARP consensus statement describing the key challenges in the management of severe asthma, and possible solutions from the perspectives of SHARP stakeholders.
- A SHARP Description of Severe Asthma across Europe – the first landmark paper mapping out the characteristics of patients living with severe asthma across Europe.
- A SHARP Description of Multimorbidities among patients living with severe asthma across Europe – for the first time providing a complete picture of the burden of multiple morbidities, guiding us towards a better and more holistic management of patients.
- A SHARP Description of patients experience of the effect of biologics.
- Other projects we expect to deliver:
 - SAQ-Burden of Asthma
 - Health Economics: the cost of OCS

- EGPA case series: EGPA that have developed after the initiation of biologics for severe asthma.
- A SHARP Research Forum where core SHARP research projects will be discussed and decided on a biannual basis.
- Establishment of the SHARP National Leads Forum where leads of the 28 national registries will work together to strengthen the synergies between best clinical practice and high-quality prospective data collection.

Finally, the achievements of the SHARP Rising Stars were celebrated by the SHARP AWARDS:

- Job van Bragt for his work on leading the Fast Mover project: Characteristics and treatment regimens across ERS SHARP severe asthma registries
- Katrien Eger for her work on co-leading the SHARP COVID-19 project
- Dora Paroczai for her work on co-leading the SHARP COVID-19 project
- Hanks Kroes for his work on leading the UNISA study
- Anne Noelle Frix for her work on leading the Use of Biologics in Europe project
- Stefania Principe for her work on leading the Characteristics of severe asthma patients on biologics; a real-life European registry study